Today as NASA's Juno spacecraft begins its third science flyby of Jupiter, there is great excitement among the scientists overseeing the mission. At the time of closest approach (called perijove), Juno will be about 4,150 kms above the gas giant's ... NetIndia123.com, 5 hours ago
Juno mission: Five things to know about NASA's Jupiter probe - Zee News, 12 hours ago
NASA's Juno probe all set to make its third Jupiter flyby on Sunday - Zee News, 1 day ago
Macquarie Group Ltd. raised its stake in Juno Therapeutics Inc. (NASDAQ:JUNO) by 84.8% during the second quarter, Holdings Channel reports. The fund owned 99,167 shares of the biopharmaceutical company's stock after buying an additional 45,517 ...Zolmax News, 1 day ago Raymond James Financial Inc. Reaffirms Market Perform Rating for Juno Therapeutics Inc. (JUNO) SleekMoney, 1 day ago Juno Sun Shine with 'the Summer That Was Ours', Out Now Broadway World, 1 day ago Raymond James softens view of Juno Therapeutics Seeking Alpha, 4 days ago
Juno Therapeutics and Kite Pharma are among the front-runners in developing chimeric antigen receptor T-cell (CAR-T) therapies to fight cancer. CAR-Ts effectively supercharge a patient's immune system to better discover and destroy cancer cells, and ...Motley Fool, 2 days ago Relapses Spell More CAR-T Uncertainty For Juno Seeking Alpha, 5 days ago Juno's reprieve? JCAR017 data a small ray of light after difficult 2016 FierceBiotech, 5 days ago Adventures in CAR-T Racing: Crashes and Curves Edition Yahoo! Finance, 1 week ago
Shares in Juno Therapeutics ( NASDAQ:JUNO ) have tumbled since the company reported a voluntary halt to its lead drug program, JCAR015, which is intended to treat acute lymphoblastic leukemia. JCAR015 attacks cancer in an entirely novel way. A ...Motley Fool, 2 days ago The Latest Buzz in Biotech Yahoo! Finance, 4 days ago
DSS, Inc. Announces Purchase Of Patient Engagement And Scheduling Solutions To Improve Care Delivery For Hospitals And Health Systems
JUNO BEACH, FLA.--(BUSINESS WIRE)-- Document Storage Systems, Inc. (DSS), the leading provider of software development and support for VistA and vxVistA, today announced a strategic agreement to acquire the Best in KLAS ForSite2020 patient ...Hospital Network .com, 4 days ago
Florida Power & Light Company presented with Davies Consulting "Communications Excellence" and "Most Innovative..
Nextera Energy, Inc. (NYSE:NEE) Intraday Stock Chart Today : Thursday 8 December 2016 JUNO BEACH, Fla. , Dec. 8, 2016 /PRNewswire/ -- Florida Power & Light Company (FPL) today announced it received Davies Consulting's "Communications ...ADVFN India, 2 days ago NEXTERA ENERGY : Florida Power & Light Company presented with Davies Consulting 'Communications Excellence' and 'Most Innovative Practice' awards 4 Traders, 2 days ago FLORIDA POWER & LIGHT COMPANY : presented with Davies Consulting "Communications Excellence" and "Most Innovative Practice" awards for its leadership in emergency response 4 Traders, 2 days ago Florida Power & Light Company - Florida Power & Light Company presented with Davies Consulting "Communications Excellence" and "Most Innovative Practice" awards for its leadership in emergency response Electric Energy Online, 1 day ago
Leaders from Fred Hutch, Seattle Cancer Care Alliance and Juno Therapeutics will speak on immunotherapy's roots in Seattle, new clinical trials and the prospects for developing new cures for cancer during a Dec. 12 scientific symposium to celebrate ...Infrosoft, 2 days ago Fred Hutch research shows immunotherapy could prevent leukemia patients from relapsing Fred Hutch, 4 days ago Experimental T-cell therapy shows promise in preventing AML relapse News-Medical.Net, 5 days ago Immunotherapy shows promise in preventing leukemia relapse EurekAlert!, 5 days ago
More from: , Fred Hutch...and 1 other sources
Image source: . What happened After reporting that it placed a key trial on voluntarily hold, shares in Juno Therapeutics ( NASDAQ:JUNO ) lost 19.3% of their value in November,according to S&P Global Market Intelligence . So what Juno ...Motley Fool, 3 days ago
Juno Therapeutics ( NASDAQ:JUNO ) just released a wave of trial data on JCAR014 and JCAR017 that it hopes will reignite investor interest, following the recent and disappointing voluntary hold that management placed last month on its lead drug ...Motley Fool, 4 days ago Juno boosted by CAR-T trial findings in NHL pharmaphorum, 4 days ago Juno turns to JCAR017 amid Rocket setback BioPharma Dive, 4 days ago CAR-T Therapy Trial Halted Due to Patient Deaths ASH Clinical News, 6 days ago
Replay Video Game Of Thrones In Numbers Newsweek Juno Listens to Jupiter's Auroras Newsweek Play Pause Seek i Volume Volume Volume Mute Unmute CC SETTINGS OFF HQ HD HQ SD LO Full Screen Exit Full Screen Play Pause Volume Volume Former England ...MSN UK, 4 days ago There's new risk that you need to consider in biotechs, Cramer warns MSN News US, 1 week ago
on your WebpageAdd Widget >Get your members hooked!